SPA
IONS icon

Sherbrooke Park Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

Sherbrooke Park Advisers’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,119
Closed -$439K – 1053
2024
Q1 		$439K Buy
10,119
+3,330
+49% +$159K 0.09% 411
2023
Q4 		$343K Buy
6,789
+1,851
+37% +$88.7K 0.16% 234
2023
Q3 		$224K Buy
+4,938
New +$204K 0.07% 377
2023
Q1 		– Sell
-7,000
Closed -$264K – 250
2022
Q4 		$264K Buy
+7,000
New +$294K 0.19% 208

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sherbrooke Park Advisers's IONS Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Ionis Pharmaceuticals (IONS) in Q2 2024, closing a stake of 10,119 shares — an estimated $439K sold.

Sherbrooke Park Advisers first reported a position in IONS in Q4 2022 and held it in 4 quarters. The position peaked at $439K in Q1 2024. 356 funds tracked by Wall St. Rank hold IONS as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Ionis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 10,119 Ionis Pharmaceuticals shares in Q2 2024, an estimated $439K.
  • Sherbrooke Park Advisers first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Ionis Pharmaceuticals position peaked at $439K in Q1 2024.
  • 356 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.